SG10202001506UA - Hepatitis b core protein allosteric modulators - Google Patents

Hepatitis b core protein allosteric modulators

Info

Publication number
SG10202001506UA
SG10202001506UA SG10202001506UA SG10202001506UA SG10202001506UA SG 10202001506U A SG10202001506U A SG 10202001506UA SG 10202001506U A SG10202001506U A SG 10202001506UA SG 10202001506U A SG10202001506U A SG 10202001506UA SG 10202001506U A SG10202001506U A SG 10202001506UA
Authority
SG
Singapore
Prior art keywords
hepatitis
core protein
allosteric modulators
protein allosteric
modulators
Prior art date
Application number
SG10202001506UA
Inventor
William W Turner
Lee Daniel Arnold
Hans Maag
Adam Zlotnick
Original Assignee
Univ Indiana Res & Tech Corp
Assembly Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp, Assembly Biosciences Inc filed Critical Univ Indiana Res & Tech Corp
Publication of SG10202001506UA publication Critical patent/SG10202001506UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/14—[b, e]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
SG10202001506UA 2014-03-13 2015-03-13 Hepatitis b core protein allosteric modulators SG10202001506UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461952467P 2014-03-13 2014-03-13
US201462010025P 2014-06-10 2014-06-10

Publications (1)

Publication Number Publication Date
SG10202001506UA true SG10202001506UA (en) 2020-04-29

Family

ID=54072461

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201607268UA SG11201607268UA (en) 2014-03-13 2015-03-13 Hepatitis b core protein allosteric modulators
SG10202001506UA SG10202001506UA (en) 2014-03-13 2015-03-13 Hepatitis b core protein allosteric modulators

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201607268UA SG11201607268UA (en) 2014-03-13 2015-03-13 Hepatitis b core protein allosteric modulators

Country Status (23)

Country Link
US (3) US10183936B2 (en)
EP (3) EP3974426A1 (en)
JP (2) JP6602311B2 (en)
KR (1) KR102363174B1 (en)
CN (2) CN106413402B (en)
AP (1) AP2016009477A0 (en)
AU (2) AU2015229174B2 (en)
CA (1) CA2942533C (en)
CL (1) CL2016002269A1 (en)
DK (1) DK3116316T3 (en)
DO (1) DOP2016000233A (en)
ES (1) ES2748029T3 (en)
HR (1) HRP20191444T1 (en)
HU (1) HUE046567T2 (en)
IL (3) IL247575B (en)
MX (2) MX363600B (en)
PH (1) PH12016501762A1 (en)
PL (1) PL3116316T3 (en)
PT (1) PT3116316T (en)
RS (1) RS59430B1 (en)
SG (2) SG11201607268UA (en)
WO (1) WO2015138895A1 (en)
ZA (1) ZA201606209B (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2797123T3 (en) 2011-12-21 2020-12-01 Novira Therapeutics Inc Antiviral agents for hepatitis B
NZ743463A (en) 2012-08-28 2019-09-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
SI2961732T1 (en) 2013-02-28 2017-07-31 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
LT2997019T (en) 2013-05-17 2018-11-26 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
AP2015008968A0 (en) 2013-07-25 2015-12-31 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives andthe use thereof as medicaments for the treatment of hepatitis b
DK3060547T3 (en) 2013-10-23 2018-01-15 Janssen Sciences Ireland Uc CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (en) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Combination therapy for treatment of hbv infections
EA035848B1 (en) 2014-02-06 2020-08-20 Янссен Сайенсиз Айрлэнд Юси Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
RS59430B1 (en) 2014-03-13 2019-11-29 Univ Indiana Res & Tech Corp Hepatitis b core protein allosteric modulators
JP2018510159A (en) 2015-03-19 2018-04-12 ノヴィラ・セラピューティクス・インコーポレイテッド Azocan and azonan derivatives and methods for treating hepatitis B infection
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10684272B2 (en) * 2015-07-15 2020-06-16 Agency For Science, Technology And Research Modulation of hepatitis B virus replication
TW201720802A (en) 2015-09-15 2017-06-16 艾森伯利生物科學公司 Hepatitis B core protein modulators
TW201718496A (en) 2015-09-29 2017-06-01 諾維拉治療公司 Crystalline forms of a hepatitis B antiviral agent
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
CN109562107A (en) 2016-05-10 2019-04-02 C4医药公司 Heterocycle degron body for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP3454862A4 (en) 2016-05-10 2020-02-12 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2018053157A1 (en) * 2016-09-15 2018-03-22 Assembly Biosciences, Inc. Hepatitis b core protein modulators
BR112019006712A2 (en) * 2016-10-03 2019-06-25 Sigilon Therapeutics Inc compound, pharmaceutical composition, composition for use in treating a disease, implantable element, and device.
US10821103B2 (en) 2016-11-07 2020-11-03 Arbutus Biopharma Corporation Substituted pyridinone-containing trycyclic compounds, and methods using same
CN106632177A (en) * 2016-12-05 2017-05-10 万特制药(海南)有限公司 Preparation method of ramelteon intermediate
HUE054822T2 (en) * 2017-02-23 2021-10-28 Fujian Cosunter Pharmaceutical Co Ltd Tri-cycle compound and applications thereof
JP2020511436A (en) 2017-03-02 2020-04-16 アッセンブリー バイオサイエンシズ，インコーポレイテッド Cyclic sulfamide compound and method of using the same
EP3596070A1 (en) * 2017-03-13 2020-01-22 Assembly Biosciences, Inc. Process for making hepatitis b core protein modulators
WO2018172852A1 (en) 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
AU2018304907B2 (en) 2017-07-21 2022-11-24 Antabio Sas Chemical compounds
JP2021501764A (en) 2017-11-02 2021-01-21 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Novel highly active aminothiazole-substituted indole-2-carboxamide effective against hepatitis B virus (HBV)
US11236087B2 (en) 2017-11-02 2022-02-01 Aicuris Gmbh & Co. Kg Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV)
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
EP3787631A4 (en) * 2018-05-03 2022-01-19 Emory University Modulators of orphan nuclear receptors for nash and other metabolic disorders
CN110627752B (en) * 2018-06-25 2021-08-17 新发药业有限公司 Preparation method of 3-aminomethyl tetrahydrofuran
CN108863884B (en) * 2018-07-26 2020-07-03 南京富润凯德生物医药有限公司 Method for synthesizing conjugated nitroene substituted series derivatives by using DAST reagent as elimination reagent
KR102397741B1 (en) * 2018-08-23 2022-05-12 푸젠 코선터 파마슈티컬 컴퍼니 리미티드 Crystal forms of tricyclic compounds and uses thereof
UY38434A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW 6,7-DIHYDRO-4H-PYRAZOLE [1,5-A] PIRAZIN INDOL-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
UY38436A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW 6,7-DIHYDRO-4H-PYRAZOLE [1,5-A] PYRAZININDOL-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
UY38437A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW UREA 6,7-DIHIDRO-4H-PIRAZOLO [1,5-A] PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
UY38435A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW UREA 6,7-DIHIDRO-4H-PIRAZOL [1,5-A] PIRAZINAS ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
UY38439A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NOVELTY UREA 6,7-DIHYDRO-4H-PYRAZOLE [4,3-C] PYRIDINES ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
TWI827760B (en) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. Targeted protein degradation
KR20210130753A (en) 2019-02-22 2021-11-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Amide derivatives useful for the treatment of HBV infection or HBV-induced disease
SG11202111493WA (en) 2019-04-30 2021-11-29 Aicuris Gmbh & Co Kg Novel oxalyl piperazines active against the hepatitis b virus (hbv)
AU2020267015A1 (en) 2019-04-30 2021-12-23 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitis B virus (HBV)
EP3962913A1 (en) 2019-04-30 2022-03-09 AiCuris GmbH & Co. KG Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
CA3138384A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
JP2022532526A (en) 2019-05-06 2022-07-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Amide derivatives useful in the treatment of HBV infections or HBV-induced diseases
SG11202112590WA (en) * 2019-05-24 2021-12-30 Assembly Biosciences Inc Pharmaceutical compositions for the treatment of hbv
CN110526878A (en) * 2019-09-16 2019-12-03 成都睿智化学研究有限公司 A kind of preparation method of 2- (oxazolyl) ethamine
CN111072551A (en) * 2019-12-30 2020-04-28 上海睿瓦科技有限公司 Method for preparing piperidine amine by catalytic hydrogenation one-step method
BR112022021419A2 (en) * 2020-04-22 2023-03-07 Assembly Biosciences Inc 5-MEM HETEROARYL CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF HBV
CN113135848A (en) * 2021-04-26 2021-07-20 深圳市华先医药科技有限公司 Preparation method of mercaptoalkenol ester compound
CN113636960A (en) * 2021-08-24 2021-11-12 上海皓元医药股份有限公司 Preparation method of 2- (chlorosulfonyl) cyclohexane-1-ethyl olefin formate derivative
CN113717080A (en) * 2021-10-09 2021-11-30 西安瑞联新材料股份有限公司 Synthesis method of 4-chloro-2-cyanobenzene sulfonyl chloride
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1480553A (en) * 1976-06-03 1977-07-20 Pfizer Ltd Tricyclic sulphonamides
JPS58225074A (en) 1982-06-25 1983-12-27 Chugai Pharmaceut Co Ltd Dibenzoazepine derivative
GB9109557D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JP2007527412A (en) * 2003-10-24 2007-09-27 エグゼリクシス， インコーポレイテッド TAO kinase modulator and methods of use
DE102004004928A1 (en) * 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
EP1937677A1 (en) * 2005-10-17 2008-07-02 Arcadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use
WO2007056388A2 (en) 2005-11-07 2007-05-18 The General Hospital Corporation Compositions and methods for modulating poly (adp-ribose) polymerase activity
US20100022509A1 (en) 2006-06-07 2010-01-28 Fahey Robert C Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
BRPI0916540B8 (en) 2008-07-23 2021-05-25 Us Health Plasmodium surface anion channel inhibitors as antimalarial agents
CN104530079B (en) * 2009-12-18 2017-10-20 北京凯因科技股份有限公司 The new inhibitor that hepatitis C virus is replicated
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
CN103889953B (en) * 2011-07-01 2016-06-08 巴鲁﹒S﹒布隆伯格研究所 As the sulfonamides heterocyclic carbamate derivatives of anti-hepatitis b virus infected antivirotic
US9968650B2 (en) 2011-07-13 2018-05-15 Indiana University Research And Technology Corporation Modified viral structural protein with antiviral activity
ES2581489T3 (en) 2012-01-06 2016-09-06 Janssen Sciences Ireland Uc 1,4,4-disubstituted 1,4-dihydropyrimidines and their use as medicines for the treatment of hepatitis B
NZ743463A (en) 2012-08-28 2019-09-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
BR112015004161B8 (en) 2012-08-28 2022-11-08 Janssen Sciences Ireland Uc FUSIONED BICYCLIC SULFAMOYL DERIVATIVE AND ITS USE IN THE TREATMENT AND PREVENTION OF INFECTION BY HEPATITIS B VIRUS, AS WELL AS PHARMACEUTICAL COMPOSITION AND PRODUCT THAT COMPRISES IT
EA201590384A1 (en) 2012-09-10 2015-10-30 Ф. Хоффманн-Ля Рош Аг 6-AMINO ACID-HETEROARYDYHYDROPYRIMIDINES FOR THE TREATMENT AND PREVENTION OF INFECTION OF THE HEPATITIS B VIRUS
CN105051017A (en) 2012-11-09 2015-11-11 美国印第安纳大学研究和技术公司 Alternative uses for HBV assembly effectors
JP6353460B2 (en) 2012-12-06 2018-07-04 バルーク エス．ブランバーグ インスティチュート Functionalized benzamide derivatives as antiviral agents against HBV infection
BR112015015584A2 (en) 2012-12-27 2017-12-12 Baruch S Blumberg Inst new antiviral agents against hbv infection
RU2519546C1 (en) 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") CONJUGATES AND SMALL MOLECULES, INTERACTING WITH CD16a RECEPTOR
SI2961732T1 (en) 2013-02-28 2017-07-31 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
AR095426A1 (en) 2013-03-14 2015-10-14 Onyx Therapeutics Inc TRIPEPTIDE INHIBITORS OF PROTEASA EPOXYCETONE
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
LT2997019T (en) 2013-05-17 2018-11-26 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
SG11201509463YA (en) 2013-05-17 2015-12-30 Hoffmann La Roche 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
AU2014281511A1 (en) 2013-06-19 2015-12-03 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
WO2015017412A1 (en) 2013-07-29 2015-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists
RS59430B1 (en) 2014-03-13 2019-11-29 Univ Indiana Res & Tech Corp Hepatitis b core protein allosteric modulators
AU2015273772A1 (en) 2014-06-10 2017-01-05 Basf Se Substituted [1,2,4]triazole and imidazole compounds as fungicides
TW201720802A (en) 2015-09-15 2017-06-16 艾森伯利生物科學公司 Hepatitis B core protein modulators
US10811219B2 (en) 2018-08-07 2020-10-20 Applied Materials Israel Ltd. Method for evaluating a region of an object

Also Published As

Publication number Publication date
CN110437153A (en) 2019-11-12
AP2016009477A0 (en) 2016-09-30
CA2942533C (en) 2020-12-08
CA2942533A1 (en) 2015-09-17
HUE046567T2 (en) 2020-03-30
KR20160135747A (en) 2016-11-28
ZA201606209B (en) 2019-04-24
NZ723972A (en) 2021-08-27
JP2019151650A (en) 2019-09-12
CN106413402B (en) 2020-10-30
US20230019129A1 (en) 2023-01-19
PH12016501762A1 (en) 2017-02-06
SG11201607268UA (en) 2016-09-29
KR102363174B1 (en) 2022-02-15
CN106413402A (en) 2017-02-15
CL2016002269A1 (en) 2017-08-18
US10947224B2 (en) 2021-03-16
HRP20191444T1 (en) 2019-11-29
IL247575B (en) 2020-05-31
AU2019203754A1 (en) 2019-06-20
US20180273521A1 (en) 2018-09-27
JP6602311B2 (en) 2019-11-06
ES2748029T3 (en) 2020-03-12
RS59430B1 (en) 2019-11-29
PT3116316T (en) 2019-09-30
EP3116316A1 (en) 2017-01-18
JP2017518959A (en) 2017-07-13
US10183936B2 (en) 2019-01-22
MX2019003525A (en) 2019-07-08
IL273132A (en) 2020-04-30
MX363600B (en) 2019-03-28
EP3116316A4 (en) 2018-05-23
DOP2016000233A (en) 2016-12-30
AU2015229174A1 (en) 2016-09-22
IL247575A0 (en) 2016-11-30
PL3116316T3 (en) 2020-03-31
EP3607950A3 (en) 2020-03-18
EP3607950A2 (en) 2020-02-12
WO2015138895A1 (en) 2015-09-17
IL273132B (en) 2021-05-31
US20170015658A1 (en) 2017-01-19
IL282391A (en) 2021-06-30
AU2015229174B2 (en) 2019-04-11
MX2016011800A (en) 2017-04-27
EP3116316B1 (en) 2019-07-10
EP3974426A1 (en) 2022-03-30
DK3116316T3 (en) 2019-08-19

Similar Documents

Publication Publication Date Title
IL282391A (en) Hepatitis b core protein allosteric modulators
HK1258697A1 (en) Hepatitis b core protein modulators
PL3303291T3 (en) Ror-gamma modulators
PL3303293T3 (en) Ror-gamma modulators
PL3303290T3 (en) Ror-gamma modulators
GB2554821B (en) Modulating processor core operations
GB201414371D0 (en) Protein modification
GB201412797D0 (en) Proteins
GB201412648D0 (en) Proteins
GB201412649D0 (en) Proteins
GB201412646D0 (en) Proteins
GB201406894D0 (en) Proteins
GB201405952D0 (en) Proteins
GB201405955D0 (en) Proteins
GB201403915D0 (en) Proteins
GB201403913D0 (en) Proteins
GB201403912D0 (en) Proteins
GB201403914D0 (en) Proteins
GB201410682D0 (en) Web-winding core